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Abstract
Streptococcus pneumoniae is a major pathogen of humans, causing diseases such as pneumonia and meningitis. The organism produces
several virulence factors that are involved in the disease process. The molecular basis of the action of some of these virulence factors
is being elucidated. The advent of whole genome sequencing combined with biological studies has demonstrated that genome variation
is important in the ability of pneumococci to interact with the host. This review discusses the biological activity of several pneumococ-
cal virulence factors, and describes how genome variation may impact on the ability of pneumococci to cause disease.
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Introduction
Streptococcus pneumoniae (the pneumococcus) colonizes the
human nasopharynx and can also cause diseases, including
otitis media, pneumonia, bacteraemia, and meningitis. The
organism produces a range of colonization and virulence fac-
tors, including the polysaccharide capsule, surface proteins and
enzymes, and the toxin pneumolysin (PLY). The role played by
virulence factors in disease has been partly elucidated. It is
clear from analysis of the increasing number of whole genome
sequences that strains of pneumococci differ in their ability to
produce virulence factors. Understanding the role played by
virulence factors allows an understanding of the pathogenesis
of infection and can be used to identify possible points of
intervention for treatment or vaccination. Understanding the
distribution of virulence factors among strains may also allow
associations to be made between these factors and the ability
to cause different types of disease. There are many pneumo-
coccal virulence factors, and this review will focus on the
capsule, the toxin, and surface-associated proteins.
Capsule
The polysaccharide capsule is probably the most important
virulence factor of the pneumococcus. The role of the
capsule in virulence stems from its antiphagocytic activity
[1]. Antibody to cell wall constituents of the pneumococ-
cus becomes attached to the surface of the organism, and
in turn binds complement. The presence of the capsule
prevents iC3b and the Fc of immunoglobulins on the bac-
terial cell surface from interacting with their receptors on
the surface of phagocytic cells, with the result that the
organisms remain extracellular [2]. The capsule is also cru-
cial for colonization, prevents mechanical removal by
mucus [3], and can also restrict autolysis and reduce
exposure to antibiotics [4].
PLY
PLY, probably the most widely studied pneumococcal protein
virulence factor, belongs to the family of pore-forming toxins
produced by more than 20 species of Gram-positive bacteria,
originally described as haemolysins. PLY is a 53-kDa protein
made by almost all clinical isolates of the pneumococcus and
expressed during the late log phase of growth [5]. Although
thought to be released only when cells undergo autolysis [6],
PLY can be released independently of the major autolysin
[7]. Initially, the toxin binds to membrane cholesterol; it then
forms large pores (up to 30 nm in diameter) by the oligo-
merization of up to 50 toxin monomers [8]. PLY also medi-
ates other effects at sublytic concentrations, including
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activation of the classic complement pathway, despite the
absence of specific antibody [9].
The role of PLY in the pathogenesis of infection has been
studied in animal models, using mutants of the pneumococ-
cus in which the gene for the toxin has been interrupted or
deleted. Early experiments with PLY) strains showed that
lack of the toxin reduces the virulence of the organism in
both intranasal and systemic routes of infection [10]. When
instilled into the mouse lung, PLY) pneumococci induce
much less inflammation [11,12]. Cell recruitment in the lung
in response to respiratory tract infections with PLY) mutants
is delayed and reduced in comparison with infection with
wild-type bacteria [12]. Neutrophil responses were the most
affected, and the redistribution of T-lymphocytes and B-lym-
phocytes in and around inflamed bronchioles was also
delayed and reduced. After intranasal infection, lack of PLY
also causes reduced numbers of bacteria in the nasopharynx,
trachea, and lungs [13], although Rubins et al. [14] showed
that PLY has no role in colonization. At lower concentra-
tions, the toxin has effects on the immune system, including
induction of the proinflammatory response, and production
of reactive oxygen intermediates and other mediators
(reviewed in [15]). These effects are potentially mediated by
the ability of PLY to interact with the lipopolysaccharide
receptor, Toll-like receptor 4 (TLR4). Macrophages from
TLR4-deficient mice do not mount an inflammatory response
to PLY. Moreover, these TLR4-deficient mice are more eas-
ily colonized and show higher susceptibility to pneumococcal
sepsis [16]. This increased susceptibility is dependent on the
presence of PLY. In addition, a mutant version of PLY in
which cytotoxic and complement-activating ability have been
removed (PdT) is still active in these assays, suggesting that
the TLR4 interaction is distinct from these activities [16]. It
has also been demonstrated, using a solid-phase assay, that
PLY physically interacts with TLR4 [17]. Protection from col-
onization with the pneumococcus has been shown to require
both TLR4 [16] and interleukin (IL)-17 [18], and both effects
appear to be dependent on PLY. IL-17 is a cytokine pro-
duced mainly from a novel subset of T-cells termed Th17
cells, and plays an important role in host defence against a
number of pathogens (reviewed in [19]). It acts to augment
neutrophil production and emigration to sites of infection
[20]. Th17 cell development requires the proinflammatory
cytokines IL-6 and IL-1b as well as transforming growth fac-
tor-b [21–23]. PLY has been demonstrated to stimulate IL-
17 production from splenocytes of mice immunized with a
combination of pneumococcal proteins [24], but it is not
clear whether this is a direct effect or requires prior stimula-
tion or co-stimulation with proinflammatory cytokines, as
has been shown for pertussis immunization [25].
The role of PLY in infections outside of the respiratory
tract is more controversial. PLY appears not to play a role
in the inflammation associated with otitis media in the chin-
chilla model [26]. Intracisternal injection of PLY into rabbit
brain causes a rapid inflammatory response, but in this study
there was no evidence for a contribution of the toxin to the
inflammation caused by the whole organism, as determined
by a comparison of wild-type and PLY) pneumococci [27].
The lack of effect of PLY on inflammation of the brain has
been confirmed in a mouse model [28]. Similar results with
regard to inflammation were seen in a guinea pig model of
infection [29]. Use of wild-type and PLY) organisms in this
system showed there to be no difference in the levels of
inflammation induced. The PLY) organism does induce less
protein influx into the cerebrospinal fluid (CSF), less ultra-
structural damage to the cochlea of infected animals, and less
associated hearing loss [29].
PLY has been shown to play a key role in brain damage
induced during pneumococcal meningitis in the rabbit
model of infection [30]. Also in the rabbit model of pneu-
mococcal meningitis, the levels of PLY released have been
measured, and shown to be about 20 ng/mL CSF [31].
This is similar to the level of toxin found in the CSF of
patients suffering from pneumococcal meningitis, which
ranges from about 1 to 180 ng/mL CSF. The level of toxin
released into the CSF during antibiotic treatment is depen-
dent on the type of antibiotic used. Much more PLY is
found in the CSF if ceftriaxone is used to treat the infec-
tion in rabbits than if a non-bacteriolytic antibody, such as
rifampin, is used [31]. This emphasizes the importance of
bacterial lysis in the release of PLY, and has important
consequences when considering the treatment of pneumo-
coccal meningitis.
The two main activities of PLY are its lytic activity and its
ability to activate complement, and regions of the protein
responsible for these activities have been identified [32]. The
use of mutants that vary in these activities has shown that
the contributions of the two activities vary according to the
type of infection. The region of the toxin that interacts with
TLR4 remains to be defined.
In summary, PLY plays several roles in infection. The toxin
appears to have no role in the inflammation associated with
meningitis [27–29], but has a role in deafness associated with
meningitis [28], and in bacteraemia [33] and pneumonia [10].
Where PLY does have a role, the contributions of comple-
ment activation and the lytic activities of the toxin to the dis-
ease process differ according to the type of infection. A
comparison of strains with point mutations that abolish the
complement activation and lytic activities of PLY with a
toxin-negative mutant suggests that PLY has other activities
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that contribute to the disease process. These activities await
further characterization.
LPXTG-anchored Surface Proteins
Analysis of the pneumococcal genome sequence indicates the
presence of some 17 putative LPXTG-anchored proteins,
although this number may vary between strains [34]. The
LPXTG motif is normally near the C-terminus of the protein,
but in some of the pneumococcal proteins it is near the
N-terminus. The N-terminal sequence may provide a
mechanism for the surface location of proteases [35]. The
C-terminal consensus is a recognition sequence for sortase
enzymes, which recognize LPXTG and anchor the protein to
the cell surface by covalent linkage of the threonine of the
motif to the pentaglycine linkage of the peptidoglycan of the
cell wall. The roles of several of these LPXTG proteins in
virulence have been investigated. These include hyaluroni-
dase, neuraminidase, and serine protease PrtA.
Hyaluronidase breaks down the hyaluronic acid compo-
nent of mammalian connective tissue and extracellular
matrix, and is secreted by 99% of clinical isolates [36]. The
degradation of hyaluronic acid may aid bacterial spread and
colonization, as demonstrated for other microorganisms
[37]. In addition, hyaluronidase may potentiate pulmonary
inflammation during pneumococcal pneumonia by complex
interactions with proinflammatory cytokines and chemokines.
Tumour necrosis factor-a and IL-1b are able to induce the
production of hyaluronic acid by fibroblasts [38]. Hyaluronic
acid can promote further cytokine secretion by binding to
CD44 on host cells.
Neuraminidase cleaves N-acetylneuraminic acid from gly-
colipids, lipoproteins and oligosaccharides on cell surfaces
and in body fluids [39]. This may cause direct damage to the
host or it may unmask potential binding sites for the organ-
ism. Loss of sialic acid as a result of neuraminidase activity
accompanies the advance of pneumococci up the Eustachian
tube to the middle ear [40]. Pneumococci have genes encod-
ing several enzymes with neuraminidase activity, and the role
of neuraminidase A (NanA) in pathogenesis has been investi-
gated. It plays a role in colonization and the development of
otitis media in the chinchilla model [41], but does not play a
role in meningitis-associated deafness [29]. NanA plays an
important role in biofilm formation, and sialic acid released
by the action of NanA may be an important signal controlling
pneumococcal virulence [42,43].
The presence of the serine protease prtA gene was origi-
nally determined in a screen of convalescent patient sera
[44], and was subsequently confirmed in all pneumococcal
isolates tested [45]. This screening for prtA, which encodes a
member of the subtilase family, also detected considerable
nucleotide sequence variation resulting in amino acid changes
across the central domain of the protein, but not affecting
the conserved catalytic triad. In a murine model of disease, a
PrtA-negative mutant of D39 was attenuated, and vaccination
provided protection from intraperitoneal challenge [45]. Sim-
ilar antibody levels are detected in healthy control individuals
and in patients with invasive disease, although there is a
trend towards increased response in early convalescence
[46]. Although the exact role of PrtA is unknown, PrtA
expression is co-regulated with a number of other virulence
genes, including the pilus locus and PLY genes, by the tran-
scription factor pneumococcal surface antigen (Psa)R [47].
Regulation of PrtA expression by PsaR has also been demon-
strated to be oppositely repressed and stimulated by manga-
nese or zinc [48].
The Pneumococcal Pilus
Pili were observed on the surface of pneumococci in 2006
[49]. The genes encoding pilus production, the rlr locus or
pilus islet 1 (PI-1), code for three structural proteins and three
sortase enzymes responsible for linking structural subunits.
The pilus is involved in virulence, and mediates binding of
pneumococci to cells. It also stimulates proinflammatory cyto-
kine production [49]. A second pilus type has been identified
in pneumococci, and is involved in adherence of pneumococci
to epithelial cells [50]. Not all pneumococci have pili, but some
strains are capable of expressing both types [50].
Lipoproteins
In a screen for pneumococcal adhesins, Cundell et al. [51]
identified mutations in genes identified as those encoding
peptide permeases, which reduce adherence to resting lung
or endothelial cells. A homologue of these permeases, PsaA,
has been ascribed a role in pneumococcal virulence [52].
PsaA is part of an ABC transporter in which PsaA is the sub-
strate-binding lipoprotein, PsaB is the ATP-binding protein,
and PsaC is the permease [53]. The complex transports
manganese ions. Mutations in psaA cause decreased adhesion
to cells, decreased virulence, and increased sensitivity to oxi-
dative stress [54–56]. The receptor for PsaA is E-cadherin
[57]. Two lipoprotein peptidyl prolyl isomerases, SlrA and
PpmA, have been shown to play a role in virulence and colo-
nization [58,59]. Pia and Piu are lipoproteins involved in iron
uptake, and these are also involved in virulence [60,61].
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Choline-Binding Proteins (CBPs)
CBPs are anchored to the cell surface via interaction of
repeat domains with choline present in the pneumococcal
cell wall. The number of CBPs present depends on the
strain of pneumococcus. There are ten in strain R6 and 15
in TIGR4 [34,62]. Several CBPs have been implicated in vir-
ulence. These include four cell wall hydrolytic enzymes
(LytA, LytB, LytC, and CbpE). LytA plays a role in viru-
lence through release of highly inflammatory cell wall deg-
radation products and also release of PLY from the
cytoplasm [63,64]. LytB, LytC and CbpE are involved in
nasopharyngeal colonization [65]. Pneumococcal surface
protein A (PspA) is an important virulence factor, as
mutants lacking this protein have reduced virulence in a
sepsis model [66]. PspA interferes with the complement
system [67] and also binds to lactoferrin [68]. Lactoferrin
plays an important part in innate immunity. Pneumococcal
surface protein C (PspC) is a multifunctional virulence fac-
tor. Its contribution to virulence varies between strains
[69]. PspC acts as an adhesin, binding to the polymeric
immunoglobulin receptor [70,71], and binds the comple-
ment regulatory protein factor H [72], to provide resis-
tance to complement.
Other Surface Proteins
Several surface proteins have been identified that do not
contain recognized anchor motifs (choline-binding, LPXTG,
or lipoprotein). Such proteins have also been reported in
other Gram-positive bacteria [73]. This family includes pneu-
mococcal adherence and virulence factor A (PavA), two gly-
colytic enzymes, glyceraldehyde-3-phosphate dehydrogenase
and enolase, and the pneumococcal histidine triad protein
(Pht) family. PavA is a crucial virulence factor, and mutants
lacking PavA are attenuated in models of sepsis and meningi-
tis [74,75]. PavA binds to fibronectin and mediates attach-
ment to endothelial cells [75]. Glyceraldehyde-3-phosphate
dehydrogenase and enolase are plasminogen-binding proteins
[76,77]. Binding of plasminogen has been shown to facilitate
transmigration of pneumococci through the basement mem-
brane [78]. The Pht family was discovered through the abil-
ity of its members to provide protection against infection
when used as vaccines [79,80]. The family consists of four
proteins: PhtA, PhtB, PhtD, and PhtE. The proteins contain
a conserved motif, HxxHHxH, that is believed to be
involved in binding of zinc ions. Expression of the Pht genes
is regulated by zinc [81], and crystallographic investigations
have shown zinc bound in the histidine motif of PhtA [82].
Mutagenesis of all four proteins is required to attenuate the
organism [81]. The Phts reduce binding of complement to
pneumococci by recruiting the complement regulator fac-
tor H [81].
Gene and Genome Variation
Genes or proteins involved in the pathogenesis and interac-
tion with the host immune system have been identified in dif-
ferent ways using available technologies. From signature-
tagged mutagenesis (STM) screens [83–85] and through
microarray analysis [86,87], various individual genes or loci
with roles in virulence have been identified. STM identifies
bacterial genes involved in pathogenesis. Interestingly, of the
more than 300 genes identified in the three STM studies,
only a small proportion are common to all three studies.
This suggests that different virulence genes may be involved
in different strains of the pneumococcus. The pneumococcus
is naturally transformable, and can take up and incorporate
DNA from closely related species [88]. For example, genetic
variation resulting in resistance to penicillin is due to acquisi-
tion of fragments of the genes encoding penicillin-binding
proteins from Streptococcus mitis, reducing the affinity of
these proteins for the drug [89]. Understanding genetic
diversity is important in understanding the virulence of pneu-
mococcal strains.
The advent of whole genome sequencing has furthered
the discovery of a number of pathogenicity islands, and lar-
ger-scale comparative genomics is further illuminating the
complexity of this organism. The genome of the pneumococ-
cus consists of 2–2.2 million base pairs, and contains
upwards of 2000 genes, depending on the strain. Genetic
heterogeneity ranges from single-nucleotide polymorphisms
to the presence or absence of large genetic islands coding
for virulence factors such as the capsule and pili. There are
more than 90 types of capsule, and these can be exchanged
by genetic recombination [90]. This type of variation has
important implications for the design of vaccines based on
capsular antigens. Variation in the presence of regions of
diversity or pathogenicity islands across a range of isolates
has been documented [87,91]. These include the pili loci for
the two types of pneumocccal pilus, described above, PI-1
[49] and the related pilus islet 2 [50], the iron uptake locus
piaABCD [92], and several other genetic loci. The PI-1 locus
is detected in around 30% of isolates, segregating with clonal
type but not serotype [93]. Through genetic diversity of the
islet, this locus itself separates into three clades [94]. Bagnoli
et al. have also reported the independent coexistence and
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expression of both pilus islets in strains from the multilocus
sequence typing clonal complex ST271. Although not as effi-
cient in adherence to host cells, the second pilus locus is
associated with emerging serotypes. Variation in pilus
expression can alter the ability of pneumococci to bind to
cells and induce inflammation [49].
Pneumococcal phages have also been described from com-
parative studies of newly sequenced genomes [95,96].
Although these appear to segregate with serotype, the role
of phage genes in either the bacterial life cycle or pneumo-
coccal disease process has yet to be determined.
Individual genes can also vary at the sequence level. For
example, the known virulence factor PspC exists as a large
number of allelic forms. Analysis of pspC sequences from
43 strains showed that the derived protein sequence had
the same domain organization, but each one had a unique
sequence that could be divided into subgroups [97]. The
majority of PspC alleles contain a C-terminal cell wall cho-
line-binding motif (see above), but 17 of the allelic variants
contain a cell wall anchor LPTXG motif instead. The contri-
bution of PspC to virulence is also known to differ
between strains [69]. A recently identified allele, pspC4.4,
contributes further to the role of the PspC protein in
avoidance of host complement by binding the inhibitor C4-
binding protein [98].
PLY is a major virulence factor of the pneumococcus (see
above). The PLY gene also exists in a number of allelic forms
[99]. One clinical strain was identified that was unable to
produce the toxin, owing to the insertion of a transposon
into the gene. Sequence variation in one of these alleles
(allele 5) results in the production of a toxin with no haemo-
lytic acivity [100]. Interestingly, strains producing this form of
the toxin (serotype 1, sequence type 306) are increasing in
prevalence in Europe [100]. Expression of allele 5 PLY is also
associated with strains of serotype 1 and serotype 8 pneu-
mococci that are associated with the ability to cause disease
outbreaks [99].
Differences in gene expression pathways may also be
involved in changes in pathogenicity. The pneumococcus has
13 two-component signal transduction systems that are
involved in regulating gene expression [101]. Mutation of
one of these systems was shown to attenuate the TIGR4
strain of the pneumococcus but not two other strains (D39
and 0100993) [102]. The mutation in TIGR4 was shown to
alter the expression of PsaA and change resistance to oxida-
tive stress. PsaA is a known virulence factor, and is a lipo-
protein that is part of a manganese transporter as well as
being an adhesin (see above). The change in PsaA expression
may result in reduced ability to acquire manganese, which, in
turn, affects the ability to resist oxidative stress. The change
in PsaA expression was not seen in the other two strains
[102].
The above examples indicate how genetic variation at dif-
ferent levels, from single-nucleotide polymorphism to genetic
island, can contribute to the disease-causing ability of pneu-
mococci.
Following the publication of a number of pneumococcal
genomes [34,62,103,104] and comparative genomic studies
[105], a core genome of 1400 genes has been calculated
[105]. As a typical pneumococcal strain such as TIGR4 has
approximately 2300 genes, such a huge capacity for genomic
diversity allows for a high degree of flexibility. This adaptabil-
ity may facilitate responses to evolutionary pressures, which
might include changes in the host environment, such as in
different stages of disease progression, or contribute to the
development of antibiotic resistance. Integrative and conjuga-
tive elements (ICEs) constitute another mechanism by which
the pneumococcus can share a larger gene pool [104]. ICE
elements have been found to carry genes for antibiotic resis-
tance, possible repair of peroxidative damage to DNA, and
the SOS response. Further evidence for the role of ICEs in
genome diversity comes from a study in group A streptococ-
cus, where genomic analysis of four new strains of group A
streptococcus showed that 41% of new genes identified
were carried on ICEs [106].
One-third of the pneumococcal genome is composed of
hypothetical proteins that have not yet been ascribed a func-
tion. The role of some of these hypothetical genes in viru-
lence is slowly being elucidated, as is the multifunctionality of
proteins not previously directly associated with virulence.
However, the combinatorial and complementary nature of
the assortment of genes required for virulence or coloniza-
tion in any given pneumococcal isolate is proving to be highly
complex. Continuation of the genome sequencing approach
and comparison across larger numbers of strains from vary-
ing serotypes and lineages will be required to truly define
the pneumococcal virulome.
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